Logo

Gilead Initiates Two P-III Studies Evaluating Remdesivir (GS-5734) for COVID-19 in the UK

Share this
Gilead Initiates Two P-III Studies Evaluating Remdesivir (GS-5734) for COVID-19 in the UK

Gilead Initiates Two P-III Studies Evaluating Remdesivir (GS-5734) for COVID-19 in the UK

Shots:

  • Gilead has initiated two P-III studies assessing the safety and efficacy of its investigational therapy- Remdesivir in patients with moderate to severe COVID-19 in the UK
  • The two studies have been granted UPHR status by the CMO and will initially involve 15 centers in the UK. Gilead is already evaluating the therapy in three ongoing clinical studies across China & the US
  • Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity demonstrated both in vitro and in animal models against Marburg- MERS- SARS- and Ebola

Click here ­to­ read full press release/ article 

Ref: Pharrmiweb | Image: Gilead


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions